collection
MENU ▼
Read by QxMD icon Read
search

Breast Cancer

shared collection
35 papers 25 to 100 followers
https://www.readbyqxmd.com/read/27137076/breast-cancer-current-molecular-therapeutic-targets-and-new-players
#1
Siddavaram Nagini
Breast cancer is the most common cancer and the most frequent cause of cancer death among women worldwide. Breast cancer is a complex, heterogeneous disease classified into hormone-receptor-positive, human epidermal growth factor receptor-2 overexpressing (HER2+) and triple-negative breast cancer (TNBC) based on histological features. Endocrine therapy, the mainstay of treatment for hormone-responsive breast cancer involves use of selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs) and aromatase inhibitors (AIs)...
May 2, 2016: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/27078711/night-work-and-breast-cancer-risk-defined-by-human-epidermal-growth-factor-receptor-2-her2-and-hormone-receptor-status-a-population-based-case-control-study-in-france
#2
Emilie Cordina-Duverger, Yves Koudou, Thérèse Truong, Patrick Arveux, Pierre Kerbrat, Florence Menegaux, Pascal Guénel
Night work has been associated with risk of breast cancer but this association needs to be confirmed. Because breast cancer is an etiologically heterogeneous disease, we explored the association of night work with breast cancer subtypes defined by tumor status (positive of negative) for estrogen-receptor (ER), progesterone-receptor (PR) and human epidermal growth factor-receptor 2 (HER2). Using the data from a case-control study in France including 975 cases and 1317 controls, we found that the odds ratios for ER+, PR+ or HER2+ breast cancers subtypes were significantly elevated, while no association with night shift work was observed for ER, PR or HER2-negative tumors...
2016: Chronobiology International
https://www.readbyqxmd.com/read/27057657/hormone-receptor-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-where-we-are-now-and-where-we-are-going
#3
REVIEW
Francesco Schettini, Giuseppe Buono, Cinzia Cardalesi, Isacco Desideri, Sabino De Placido, Lucia Del Mastro
Near 75% of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone receptors (PgR), while up to 20% of BC show an overexpression/amplification of Human Epidermal Growth Factor Receptor 2 (HER2). Around 50% of all HER2-overexpressing BC show the coexistence of both HER2 overexpression/amplification and ER and/or PgR overexpression. Numerous in vitro and in vivo studies suggest the existence of a cross-talk between their downstream pathways, which seem to affect the natural history, response to therapy and outcome of patients affected by this subset of BC...
May 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/26914222/association-of-pathologic-complete-response-to-neoadjuvant-therapy-in-her2-positive-breast-cancer-with-long-term-outcomes-a-meta-analysis
#4
Kristine R Broglio, Melanie Quintana, Margaret Foster, Melissa Olinger, Anna McGlothlin, Scott M Berry, Jean-François Boileau, Christine Brezden-Masley, Stephen Chia, Susan Dent, Karen Gelmon, Alexander Paterson, Daniel Rayson, Donald A Berry
IMPORTANCE: The expense and lengthy follow-up periods for randomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical and even impossible to conduct. Randomized clinical trials of neoadjuvant systemic therapy for breast cancer may help resolve this dilemma. OBJECTIVE: To assess the utility of pathologic complete response (pCR) for neoadjuvant drug development in human epidermal growth factor receptor 2 (HER2 [also referred to as ERBB2])-positive breast cancer...
June 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/26917603/a-multicenter-phase-ii-study-evaluating-the-efficacy-safety-and-pharmacokinetics-of-trastuzumab-emtansine-in-japanese-patients-with-heavily-pretreated-her2-positive-locally-recurrent-or-metastatic-breast-cancer
#5
Masahiro Kashiwaba, Yoshinori Ito, Shintaro Takao, Hiroyoshi Doihara, Yoshiaki Rai, Kazumitsu Kanatani, Shigemitsu Takashima, Norikazu Masuda
OBJECTIVE: Trastuzumab emtansine significantly improved progression-free survival and overall survival when compared with lapatinib-capecitabine in pretreated human epidermal growth factor receptor 2-positive advanced breast cancer. However, data in Japanese populations are limited. METHODS: In the single-arm Phase II JO22997 study, Japanese patients with human epidermal growth factor receptor 2-positive inoperable locally advanced/recurrent or metastatic breast cancer previously treated with at least one prior chemotherapy regimen for locally advanced/recurrent or metastatic breast cancer and trastuzumab in any setting received 3...
May 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26897275/cardiomyopathy-associated-with-targeted-therapy-for-breast-cancer
#6
REVIEW
Kamesh Sivagnanam, Zia U Rahman, Timir Paul
BACKGROUND: Chemotherapeutic agents directed against human epidermal growth factor receptor 2 (HER-2) have significantly improved the prognosis of patients who are positive for this receptor. However, cardiomyopathy remains as a common adverse effect of using these agents. MATERIALS AND METHODS: Literature search was conducted via PubMed using the keywords of "Trastuzumab Cardiomyopathy," "Lapatinib Cardiomyopathy" and "Pertuzumab Cardiomyopathy," which provided 104 results...
February 2016: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/26617210/the-role-of-postmastectomy-radiation-therapy-in-patients-with-breast-cancer-responding-to-neoadjuvant-chemotherapy
#7
REVIEW
Jose G Bazan, Julia R White
When surgery is the first line of breast cancer treatment, numerous randomized clinical trials and meta-analyses have demonstrated that postmastectomy radiation therapy (PMRT) improves locoregional control and survival for many women with axillary lymph node-positive disease. In contrast, there are no randomized data regarding the use of PMRT in women who receive neoadjuvant chemotherapy (NAC) first followed by mastectomy. This has led to controversy regarding which patient with breast cancer will benefit from PMRT after NAC, particularly in women with clinically node-positive axillary disease that responds well and is down staged to pathologically negative disease at surgery (ypN0)...
January 2016: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/26677438/biomarkers-in-triple-negative-breast-cancer-a-review
#8
REVIEW
Budhi S Yadav, Priyanka Chanana, Swaty Jhamb
Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of breast cancer are diagnosed annually and more than 170000 are triple-negative. Characteristic feature of triple negative breast cancer (TNBC) is that it lacks expression of oestrogen, progesterone and human epidermal growth factor receptor-2/neu receptors. They comprise 15%-20% of all breast cancers. We did a systematic review of PubMed and conference databases to identify studies published on biomarkers in TNBC. We included studies with biomarkers including: Epidermal growth factor receptor, vascular endothelial growth factor, c-Myc, C-kit and basal cytokeratins, Poly(ADP-ribose) polymerase-1, p53, tyrosinase kinases, m-TOR, heat and shock proteins and TOP-2A in TNBC...
December 10, 2015: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26473525/use-of-trastuzumab-for-her2-positive-metastatic-breast-cancer-in-daily-practice-a-population-based-study-focusing-on-the-elderly
#9
Johan M van Rooijen, Linda de Munck, Guusje M Teeuwen, Jacques C de Graaf, Frank G Jansman, James E Boers, Sabine Siesling
The addition of trastuzumab to chemotherapy in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) prolongs overall survival (OS) in clinical trials. However, treatment patterns and survival in daily practice are unknown. This study aims to compare trastuzumab use and outcome in HER2-positive MBC patients in a population-based cohort with clinical trial cohorts, with a special focus on elderly patients. MBC patients treated with trastuzumab-based chemotherapy in north-east Netherlands between 2005 and 2009 were identified from 23 hospital pharmacies and the Netherlands Cancer Registry...
February 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/26397225/role-of-her2-mutations-in-refractory-metastatic-breast-cancers-targeted-sequencing-results-in-patients-with-refractory-breast-cancer
#10
Yeon Hee Park, Hyun-Tae Shin, Hae Hyun Jung, Yoon-La Choi, TaeJin Ahn, Kyunghee Park, Aeri Lee, In-Gu Do, Ji-Yeon Kim, Jin Seok Ahn, Woong-Yang Park, Young-Hyuck Im
In women with metastatic breast cancer (MBC), introduction of the anti-HER2 (human epidermal growth factor receptor-2) directed therapies including trastuzumab, pertuzumab, lapatinib, and/or trastuzumab-DM1 has markedly improved overall survival. However, not all cases of HER2-positive breast tumours derive similar benefit from HER2-directed therapy, and a significant number of patients experience disease progression because of primary or acquired resistance to anti-HER2-directed therapies. We integrated genomic and clinicopathological analyses in a cohort of patients with refractory breast cancer to anti-HER2 therapies to identify the molecular basis for clinical heterogeneity...
October 13, 2015: Oncotarget
https://www.readbyqxmd.com/read/26352893/immunology-and-breast-cancer-toward-a-new-way-of-understanding-breast-cancer-and-developing-novel-therapeutic-strategies
#11
REVIEW
Isabelle Gingras, Hatem A Azim, Michail Ignatiadis, Christos Sotiriou
Every cancer triggers an immune response that constitutes an important first-line protection against cancer progression. In breast cancer, there is an increasing awareness of the relationship between the immune system and tumor evolution. The tumor microenvironment is composed of a variety of immune cells that can control or arrest malignant progression. Chemotherapy and targeted therapy have been shown to modulate this immune microenvironment. Recently, tumor-infiltrating lymphocytes have emerged as a predictive and prognostic biomarker in early breast cancer...
June 2015: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/26388292/immunotherapeutic-options-on-the-horizon-in-breast-cancer-treatment
#12
REVIEW
Johan M van Rooijen, Thijs S Stutvoet, Carolien P Schröder, Elisabeth G E de Vries
It is increasingly acknowledged that breast cancer can be an immunogenic disease. Immunogenicity appears to differ between subtypes. For instance, in triple negative breast cancer (TNBC) and HER2-positive breast cancer tumor infiltrating lymphocytes (TILs) are prognostic and predictive for response to chemotherapy containing anthracyclines, but in other subtypes they are not. Preclinical evidence suggests important immune based mechanisms of conventional chemotherapeutics, in particular anthracyclines. Early clinical studies with monoclonal antibodies targeting programmed death protein 1, programmed death-ligand 1 and cytotoxic T-lymphocyte-associated antigen 4 have shown anti-tumor efficacy...
December 2015: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/26422389/high-her2-protein-levels-correlate-with-increased-survival-in-breast-cancer-patients-treated-with-anti-her2-therapy
#13
Paolo Nuciforo, Sheeno Thyparambil, Claudia Aura, Ana Garrido-Castro, Marta Vilaro, Vicente Peg, José Jimenez, Rocio Vicario, Fabiola Cecchi, William Hoos, Jon Burrows, Todd Hembrough, Juan Carles Ferreres, José Perez-Garcia, Joaquin Arribas, Javier Cortes, Maurizio Scaltriti
INTRODUCTION: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments. METHODS: Using selected reaction monitoring mass spectrometry (SRM-MS), we quantified HER2 protein levels in formalin-fixed, paraffin-embedded (FFPE) tissue samples that had been classified as HER2 0, 1+, 2+ or 3+ by immunohistochemistry (IHC)...
January 2016: Molecular Oncology
https://www.readbyqxmd.com/read/26376461/meta-analysis-of-randomized-controlled-trials-for-the-incidence-and-risk-of-treatment-related-mortality-in-patients-with-breast-cancer-treated-with-her2-blockade
#14
Junyan Wu, Kaifeng Qiu, Jianhong Zhu, Jianfang Li, Yin Lin, Zhichao He, Guocheng Li
PURPOSE: The association between human epidermal growth factor receptor-2 (HER2) blockades and risk of fatal adverse events (FAEs) has not been well described. We carried out a meta-analysis regarding this issue. METHODS: An electronic search of Medline, Embase and The Cochrane Central Register of Controlled Trials was conducted to investigate the effects of anti-HER2 therapies on cancer patients. Only randomized controlled trials were included. Random or fixed-effect meta-analytical models were used to evaluate the risk ratio (RR) of FAEs due to the use of HER2 blockades...
December 2015: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/26389758/trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer-previously-treated-with-chemotherapy-and-2-or-more-her2-targeted-agents-results-from-the-t-pas-expanded-access-study
#15
MULTICENTER STUDY
Denise A Yardley, Ian E Krop, Patricia M LoRusso, Musa Mayer, Brian Barnett, Bongin Yoo, Edith A Perez
PURPOSE: The antibody-drug conjugate trastuzumab emtansine (T-DM1) has improved outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), as demonstrated in phase III studies. Few data approximating its use in routine clinical practice are available. METHODS: The T-DM1 Patient Access Study was an expanded-access, multicenter study of T-DM1 in US patients with pretreated HER2-positive locally advanced breast cancer or MBC...
September 2015: Cancer Journal
https://www.readbyqxmd.com/read/26314782/primary-breast-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#16
E Senkus, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, E Rutgers, S Zackrisson, F Cardoso
No abstract text is available yet for this article.
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26351332/cost-effectiveness-of-pertuzumab-in-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer
#17
RANDOMIZED CONTROLLED TRIAL
Ben Y Durkee, Yushen Qian, Erqi L Pollom, Martin T King, Sara A Dudley, Jenny L Shaffer, Daniel T Chang, Iris C Gibbs, Jeremy D Goldhaber-Fiebert, Kathleen C Horst
PURPOSE: The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. We performed a cost-effectiveness analysis to assess the value of adding pertuzumab. PATIENT AND METHODS: We developed a decision-analytic Markov model to evaluate the cost effectiveness of docetaxel plus trastuzumab (TH) with or without pertuzumab in US patients with metastatic breast cancer...
March 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26348887/prognosis-for-patients-with-metastatic-breast-cancer-who-achieve-a-no-evidence-of-disease-status-after-systemic-or-local-therapy
#18
Andrew J Bishop, Joe Ensor, Stacy L Moulder, Simona F Shaitelman, Mark A Edson, Gary J Whitman, Sandra Bishnoi, Karen E Hoffman, Michael C Stauder, Vicente Valero, Thomas A Buchholz, Naoto T Ueno, Gildy Babiera, Wendy A Woodward
BACKGROUND: This study sought to determine outcomes for patients with metastatic breast cancer (MBC) with no evidence of disease (NED) after treatment and to identify factors predictive of outcomes once the status of NED was attained. METHODS: This study reviewed 570 patients with MBC who were consecutively treated between January 2003 and December 2005. Ninety patients (16%) attained NED, which was defined as a complete metabolic response on positron emission tomography or sclerotic healing of bone metastases on computed tomography or magnetic resonance imaging...
December 15, 2015: Cancer
https://www.readbyqxmd.com/read/26318110/which-women-with-breast-cancer-do-and-do-not-undergo-receptor-status-testing-a-population-based-study
#19
Marianna de Camargo Cancela, Harry Comber, Linda Sharp
INTRODUCTION: Receptor status determines of breast cancer treatment and prognosis. In a population-based study, we investigated predictors of receptor test receipt. MATERIALS AND METHODS: Invasive breast cancers diagnosed 2006-2008 were abstracted from the National Cancer Registry Ireland. Modified Poisson regression with robust error variance was used to identify socio-demographic, health service and clinical predictors of not undergoing ER, PR or HER2 testing...
October 2015: Cancer Epidemiology
https://www.readbyqxmd.com/read/26299406/long-term-side-effects-of-adjuvant-chemotherapy-in-patients-with-early-breast-cancer
#20
REVIEW
Jessica J Tao, Kala Visvanathan, Antonio C Wolff
Adjuvant systemic therapy along with screening has been key to the observed improvements in disease-free and overall survival (DFS/OS) in breast cancer. Improvements in overall survival already take into account therapy related toxicities that can result in death. However, this measure alone does not adequately capture the impact on health-related quality of life. Therefore, it is important to examine the prevalence, frequency and short/long-term impact of therapy-related toxicities, identify patients who might be at greatest risk...
November 2015: Breast: Official Journal of the European Society of Mastology
label_collection
label_collection
4737
1
2
2015-09-07 04:08:52
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"